Last reviewed · How we verify
NCT03638388
Dry Needling vs Dry Needling With ES in Patients With Neck/Shoulder Pain
NA trial testing Dry needling (DN) in Myofascial Pain in 45 participants. Completed in 1 February 2019.
1 December 2018
Quick facts
| Lead sponsor | Kindyle Brennan |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 45 |
| Start date | 16 August 2018 |
| Primary completion | 1 December 2018 |
| Estimated completion | 1 February 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Dry needling (DN)
- Dry needling with intramuscular electrical stimulation (DNES)
Conditions studied
- Myofascial Pain — all drugs for Myofascial Pain →
- Neck Pain — all drugs for Neck Pain →
- Shoulder Pain — all drugs for Shoulder Pain →
Sponsor
Kindyle Brennan
Who can join
Adults 18 to 60, any sex, with Myofascial Pain or Neck Pain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
First, we aim to determine if there is a difference in the rate of improvement, as measured by the Neck Disability Index (NDI) and Numerical Pain Rating Scale (NPRS), across a 6 week treatment period between those treated with DN only and those treated with DN and intramuscular electrical stimulation (IES) in subjects with upper trapezius active trigger points (aTrPs). Secondly, we want to determine if improvements in clinical outcomes (NDI and NPRS) of patients with upper trapezius active trigger points (aTrPs) treated with dry needling (DN) alone or dry needling with intramuscular electrical stimulation (DN/IES) are maintained 6 weeks post treatment without further intervention. Research Questions: 1. Is there a difference in the rate of improvement in NDI and NPRS across a 6 week treatment period in subjects with upper trapezius active trigger points (aTrPs) between those treated with DN only and those treated with DN and intramuscular electrical stimulation (IES)? 2. Are improvements in clinical outcomes (NDI and NPRS) of patients with upper trapezius active trigger points (aTrPs) treated with dry needling (DN) maintained 6 weeks post treatment without further intervention? Tertiary exploration: If improvement is maintained, is there a difference in outcome maintenance between groups? Did improvement increase between 6 and 12 weeks?
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Rate and maintenance of improvement of myofascial pain with dry needling alone vs. dry needling with intramuscular electrical stimulation: a randomized controlled trial.
Brennan K, Elifritz KM, Comire MM, Jupiter DC. · · 2021 · cited 15× · PMID 32990529 · DOI 10.1080/10669817.2020.1824469
Verify or expand the search:
- PubMed search for NCT03638388
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Dry needling (DN)
Trials testing the same drug.
- NCT07397039 — Efficacy of Focused ESWT and Dry Needling Among Patients With Myofascial Pain Syndrome of the Upper Trapezius Muscle · NA · completed
Other recruiting trials for Myofascial Pain
Currently open trials in the same condition.
- NCT07278570 — Magnetic Resonance Elastography to Monitor Response to Manual Therapy in Myofascial Pain · NA · recruiting
- NCT06036524 — Multi-modal Imaging of Myofascial Pain · NA · active not recruiting
- NCT05793086 — Evaluation of a Novel Class of Objective Myofascial Pain Assessments · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03638388 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kindyle Brennan
- Last refreshed: 25 March 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03638388.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing